The Foundation for the NIH (FNIH), National Cancer Institute (NCI) and partners are launching a three-year initiative to determine whether minimal residual disease (MRD) can be used to predict response to therapy in adult Acute Lymphoblastic Leukemia (ALL). Learn more from the full press release.
Welcome to the Cancer Diagnosis Program!
The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.
For more information about the Cancer Diagnosis Program and its Branches, please click here.
News and Announcements
There are currently no scheduled events